HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer

doi:10.12998/wjcc.v7.i15.1964

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8247)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

583

WORD

299

HTML

4174

Figures (1-5)

418

Tables (1-2)

316

Sum=5790

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1061

Download

1396

Sum=2457

Aug 6, 2019 (publication date) through Jan 23, 2025

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Aug 6, 2019; 7(15): 1964-1977
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1964

Full Size Figure Download Figure

Figure 4 OS and PFS with or without intratumoral human epidermal growth factor receptor 2 heterogeneity. Kaplan-Meier curves of OS (left) and PFS (right) in both groups was shown with the median follow-up of 18.5 mo (range, 4.7-88.0 mo). MST and median PST in the Hetero group were significantly worse than those in the Homo group. MST: Median survival time; HR: Hazard ratio; CI: Confidence interval; OS: Overall survival; PFS: Progression-free survival.

Citation: Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases 2019; 7(15): 1964-1977
URL: https://www.wjgnet.com/2307-8960/full/v7/i15/1964.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i15.1964